English | French | Spanish | Russian

English | French | Spanish | Russian

Classified as Internal
www.gavi.org
Sept 30 Extraordinary Board
Meeting
COVAX Facility
Seth Berkley, CEO
Board meeting
29 -30 September 2020
Classified as Internal
COVAX Facility
latest sign -up
numbers
Update: SEPT 30
2
76 higher income economies have now joined the COVAX Facility covering >1 B
people with 47 individual commitments + 29 from ?Team Europe?
Combined with AMC92, this means a total of 168 economies , representing nearly two -
thirds of the global population , are now committed to or eligible to receive vaccines
through the Facility
A further 25 economies still indicating they will sign on as soon as they can = up to 193
economies
Current SFP volume is 444M and it is expected to increase by ~35% with the added
subscription, reaching a total of 601 M doses
With 92 AMC economies representing 3.9 B people, COVAX Facility could provide for
5.8 B people and a total volume of 1.7 B doses

1



Board -2020 -Mtg -5-Doc 03


Section A: Summary
Context
In July 2020 , the Gavi Board approved Gavi as the legal entity to administer the
COVAX Facility (the ? Facility ?), a global mechanism to pool resources and demand
for COVID -19 vaccines with the goal of accelerating the availability of and equitable
access to safe and e fficacious vaccines. The Board also approved the
establishment of the Gavi COVAX AMC (the ? COVAX AMC ?), a financing
mechanism to accelerate and reserve COVID -19 vaccines to ensure that low
income and lower middle -income economies, as well as other IDA -elig ible
economies , have access to COVID -19 vaccines at the same time as wealthier
economies .
The COVAX Facility will have global participation of over 170 economies
representing over 70% of the world?s population. As this paper is being written,
self -financi ng economies have begun to provide their legally binding agreements
which include upfront funding to reserve doses with manufacturers now. This will
allow the Facility to build an actively managed portfolio of 10 -15 vaccine candidates
based upon diverse technologies and geographies to maximise the chance of a
successful outcome and accelerate access with up to two billion doses by end of
2021. The COV AX Facility will shape the vaccine market to expand supply and
achieve economies of scale through aggregating demand and increasing
availability simultaneously in developed and developing countries.
Without a successful COVAX Facility there is a very real risk that lower income
countries will be left behind, and the majority of people in the world will go
unprotected. This would allow the virus and the pandemic to continue unabated
and continue to disrupt the global economy as well as Gavi ?s core mission . The
Gavi Secretariat, including the Office of the COVAX Facility , under the guidance of
the Board, must find the right balance to safe guard the reputation and finances of
the Alliance and successfully deliver on the promise of the Facility. To this end, the
COVAX Facility is designed to ensure the procurement and governance needs of
both Self -Financing Participants (?SFP?) and 92 COVAX AMC -eligible economies
(?AMC92?) are adequately addressed whilst minimising risks to Gavi core
resources and programmes.

SUBJECT : COVAX FACILITY OPERATIONALISATION AND VACCINE
PROGRAMME
Agenda item: 03
Category: For Decision
Report to the Board
29 -30 September 2020

Doc 03 ? Annex F

Classified as Internal

September 2020
COVAX AMC STAKEHOLDERS GROUP
TERMS OF REFERENCE
1. Purpose
The Gavi COVID -19 vaccine (?COVAX?) Advance Market Commitment (?AMC?) Stakeholders
Group is established by the Board of the Gavi Alliance (?Gavi?) to convene the AMC
Stakeholders with the aims of performing the functions as set out in the Stakeholders
Agreement and receiving information about the AMC from the Gavi Secretariat. These aims
are in support of the objective of the AMC, which is to reduce the impact of C OVID -19 within
AMC eligible economies by accelerating the introduction and scale up of vaccines that protect
against COVID -19.
2. Membership
The following shall be members of the Stakeholders Group:
o Founding members of the PCV AMC and which decide to transfer their surplus funds from
the PCV AMC to the AMC;
o Countries entering into AMC Grant Agreements for more than US$10 million;
o Private and/or not -for -profit donors entering into AMC Grant Agreement s for more than
US$ 10 million;
o Multilateral development banks providing support to the AMC
The COVAX Facility Procurement Coordinator and PAHO will also be invited to attend the
Stakeholders Group as observers.
A. Composition and size
Each Member may appoint one formal representative to the Stakeholders Group. All
members are treated equally in terms of membership, rights and privileges .
B. Competencies and skills
Stakeholders Group representatives should be empowered to represent their government?s
or o rganisation?s policies and priorities, and reach agreements on their behalf. M embers are
expected to be willing and able to dedicate sufficient time to fulfil Stakeholders Group roles
and responsibilities. All members are expected to act in a manner cons istent with the
Facility?s goals.
The criteria for Stakeholders Group membership shall be consistent with Gavi?s guiding
principles on gender for Board and Board Committee nominations and Gavi?s Conflicts of
Interest Policy for Governance Bodies.

Doc 03 ? Annex G

Classified as Internal





September 2020
COVAX FACILITY CONSENSUS GROUP
TERMS OF REFERENCE

1. Purpose
The COVAX Facility Consensus Group (? the COVAX Consensus Group?) is established by the Board
of the G avi Alliance (?Gavi?) to support effective operation of the COVAX Facility (? the F acility?)
through consensus -based decision -making .
2. Membership
The COVAX Consensus Group shall comprise the Chair and Vice Chair of the Gavi Board; the Co -
Chairs of the COVAX Shareholders Council; the Co -Chairs of th e COVAX AMC Engagement Group ;
and ? in an ex -officio , non -voting, capacity - the three leads of the ACT -Accelerator vaccine pillar,
namely the CEO of Gavi , the CEO of CEPI (Coalition for Epidemic Preparedness Innovations) and
the Chief Scientist of WHO .
The COVAX Consensus Group shall be chaired by the Gavi Board Chair.
The work of the COVAX Consensus Group will be supported by a Secretary from the Office of the
COVAX Facility.
3. Authority
The COVAX Consensus Group serves as a platform to reach consensus within the Facility on
matters arising where all other possible avenues to resolve the matters have been exhausted .
It will have reasonable access to information, gover nance bodies, personnel, and relevant other
parties within the Facility, as well as external expertise, as required to achieve consensus .
Decisions reached by the COVAX Consensus Group are final.
4. Responsibilities
The COVAX Consensus Group is responsible to ensure that any disputes or challenges arising in
the governance bodies of the Facility can be addressed swiftly and in the best interests of the aims
of the Facility.

Doc 03 ? Annex E

Classified as Internal
September 2020
COVAX AMC ENGAGEMENT GROUP
TERMS OF REFERENCE
1. Purpose
The COVAX Facility Advance Market Commitment (?AMC?) Engagement Group (?the AMC
Group ?) is established by the Board (?Board?) of the Gavi Alliance (?Gavi?) to convene
representatives from implementing countries, donors and other parties engaged in the
financing and operation of the AMC portion of the Facility , with the aim of providing st rategic
guidance and advice to the Office of the COVAX Facility (?the Office?) on the operational
aspects of the COVAX Facility .
The AMC Group i s not deemed to be a committee of the Board in that its primary role is
essentially an advisory function as cont emplated under Article 20 of the Statues. It is
empowered by the Board to undertake the responsibilities outlined in these terms of
reference.
2. Membership
Membership of t he AMC Group will be open to representatives of implementing countries,
donors and other parties engaged in the financing and operation of the AMC portion of the
Facility .
A. Composition and size
Given the large number of parties engaged in the AMC, it is expected that the AMC Group will
normally meet as a representative group, drawing on Gavi Implementing Country Board
members, representatives of the non -Gavi AMC countries, and other relevant Board members.
All members are treated equally in terms of membership, rights and privileges .
B. Competencies and skills
All members are expected t o act in a manner consistent with the Facility?s goals.
The criteria for AMC Group membership shall be consistent with Gavi?s guiding principles on
gender for Board and Board Committee nominations and Gavi?s Conflicts of Interest Policy for
Governance Bodies.
AMC Group Co -Chairs shall be selected from among its members . The Co -Chairs sh ould
normally comprise one Co -Chair from a n AMC donor and one fro m an AMC funded
participant .
The Co -Chairs of the Council shall:
o Plan, lead and facilitate the conduct of AMC Group meetings;
o Facilitate and summarise discussions objectively and with clari ty seeking to gain
consensus and exert authority when necessary;